<DOC>
	<DOCNO>NCT02809963</DOCNO>
	<brief_summary>The aim study investigate effect selective blocking mineralocorticoid receptor patient type 2 diabetes insulin resistance , lipid metabolism myocardial function .</brief_summary>
	<brief_title>Mineralocorticoid Receptor Antagonists Type 2 Diabetes</brief_title>
	<detailed_description>In randomize , double-blind , placebo-controlled study want investigate effect mineralocorticoid receptor antagonists type 2 diabetes patient myocardial function , glucose fat metabolism . Background The mortality rate T2 DM still increase almost factor 2 although poly pharmacological therapy risk factor recommend year . Treatment MR antagonists patient primary hyperaldosteronism systolic heart failure improve insulin resistance , myocardial function prognosis . Further , recent evidence suggest aldosterone participates regulation glucose lipid metabolism , MR expression identify adipocytes beneficial metabolic effect selective MR blockade demonstrate several animal model . Notably , available data human T2DM . A key feature T2 DM alter body composition characterize increase metabolic active visceral adipose tissue ( VAT ) increase fat content liver , associate cardiac dysfunction outcome . Gold standard measurement VAT magnetic resonance imaging ( MRI ) , proton MRI spectroscopy quantitatively measure fat content liver high precision . The pathogenesis myocardial dysfunction T2DM link insulin resistance ( IR ) adipose tissue mediating increase supply free fatty acid intra myocardial lipid accumulation . Thus , beneficial effect lipid metabolism could theory indirectly improve myocardial function type 2 diabetic . Global longitudinal strain ( GLS ) validate method evaluate regional global function leave ventricle , strong predictor incident HF patient myocardial infarction closely related plasma NT-proBNP concentration . Hypothesis Selective block MR receptor patient T2 DM improve insulin resistance , lipid metabolism myocardial function . Objectives To investigate effect Eplerenone 100-200 mg daily compare placebo patient type 2 diabetes regard glucose lipid metabolism , myocardial function structure , vascular function . The primary objective investigate effect Eplerenone 100-200 mg daily compare placebo change liver fat content . Design A single center , randomize , double blind placebo control trial . Patients T2 DM high risk cardiovascular disease randomize either Eplerenone 100-200 mg placebo daily 26 week . Patients investigated baseline 26 week . A total 130 patient type 2 diabetes include .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Mineralocorticoid Receptor Antagonists</mesh_term>
	<mesh_term>Eplerenone</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Mineralocorticoids</mesh_term>
	<criteria>Able understand write patient information give inform consent Type 2 diabetes mellitus ( WHO criteria ) , diagnose least 3 month prior baseline Blood pressure treatment accord standard guideline Negative pregnancy test ( fertile woman ) Be willing change/pause potassium spar medication Age 1885 year Patients must high cardiovascular risk factor , define one following : NTproBNP ≥ 70 pg/ml ( take within last 6 month prior baseline ) Albuminuria ( albumin/creatinine ratio ≥ 30 mg/g Confirmed history myocardial infarction ( ≥ 3 month prior baseline ) Or patient discharge hospital document diagnosis unstable angina within 24 month prior baseline Evidence coronary artery disease CAG 1 major coronary artery OR least one following : positive noninvasive stress test , OR positive stress echocardiography show regional systolic wall motion abnormality , OR positive scintigraphy test showing stressinduced ischemia History ischemic hemorrhagic stroke ( ≥ 3 month prior inform consent ) Presence peripheral artery disease ( symptomatic ) document either : previous limb angioplasty , stenting bypass surgery ; previous limb foot amputation due circulatory insufficiency ; angiographic evidence significant ( ≥ 50 % ) peripheral artery stenosis least one limb ; evidence noninvasive measurement significant ( ≥50 % report hemodynamically significant ) peripheral artery stenosis least one limb ; ankle brachial index ≤ 0.9 Left ventricle hypertrophy : Documented echocardiography ECG : Rspike V5/V6 ≥ 25 mm Sspike V1 + Rspike V5/V6 ≥ 35 mm Patients without cardiovascular risk factor randomize fat biopsy sub study . Allergic study medication Systolic HF ( LVEF ≤ 40 % ) Impaired kidney function , eGFR ≤ 40 ml/min Severe liver insufficiency ( ChildPugh class C ) Treatment MR antagonist within 3 month prior baseline Treatment ACE inhibitor Angiotensin II Receptor blocker . Serumpotassium ≥ 5.0 mmol/l Serumsodium ≤ 135 mmol/l Myocardial infarction , unstable angina pectoris bypass graft surgery within 3 month prior baseline Persistant atrial fibrillation ( except fat biopsy sub population ) ECG show malign ventricular arrhythmia prolong QTinterval ( &gt; 500ms ) Untreated heart valve disease ICDunit/pacemaker Pregnancy desire hereof breastfeed Women fertile age use safe contraceptive ( spiral , hormonal contraceptive ) Cancer unless complete remission ≥ 5 year Alcohol/drugabuse Inflammatory bowel disease Other concomitant disease treatment accord investigator 's assessment make patient unsuitable participate study Simultaneous participation another clinical study Treatment CYP3A4inhibitors ( e.g . itraconazol , etoconazol , ritonavir , nelfinavir , clarithromycin , telithromycin nefazodon )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>